




Novel, first-in-class small molecule inhibitors  
targeting tau for neurodegeneration




James Moe, Ph.D., MBA  
President and CEO  
[jmoe@oligomerix.com](mailto:jmoe@oligomerix.com)

## Global Dementia Prevalence Increase




Patient  
Population  
(millions)




## Growing Cost of US Healthcare for Dementia




Healthcare  
Cost  
(\$ Billions)






- **Tau aggregation** plays a pivotal role in many neurodegenerative diseases called **Tauopathies**
- **No approved treatments for Tauopathies**
- Most **Tauopathies** are **rare diseases**
  - Accelerated regulatory pathways


## Lead Compound Profile - OLY07010



- **First-in-class small molecule** inhibitor of tau self-association
- Demonstrated **in vivo proof-of-concept (POC)**
- Preparing to enter **first-in-human clinical development**
- Initial focus on **rare diseases** in the clinic, then AD
- Patent Protection:
  - Small molecule **patents pending**
  - Four **issued patents** around target and biomarkers




Reduction of tau self-association in vivo




# THERAPEUTIC EFFICACY IN AGED TAU ANIMAL MODEL



## Reduction in tau pathology



## Improvement in motor function




## Reduction in tau pathology in models of tau aggregation




**In vivo POC for preventive therapy**

- **Ph 1a:** Conduct **SAD MAD**, healthy adults and **elderly cohort**
- **Ph 1b:** Current plan = **AD + PSP**
- Potential for:
  - Early clinical efficacy
  - Expedited regulatory & commercial path





# Timeline Through Phase 1a



**Adam L. Boxer, MD, PhD**

Endowed Professor in Memory and Aging  
Director, Neurosciences Clinical Research Unit  
Director, Alzheimer's Disease and Frontotemporal  
Dementia Clinical Trials Program  
University of California San Francisco  
San Francisco, CA

**Jeffrey Cummings, MD, ScD**

Joy Chambers-Grundy Professor of Brain Science  
Director, Chambers-Grundy Center for Transformative Neuroscience  
Department of Brain Health, School of Integrated Health Sciences  
University of Nevada Las Vegas (UNLV)  
Las Vegas, NV

**Martin R. Farlow, MD**

Professor Emeritus  
Department of Neurology  
Indiana University School of Medicine  
Associate Director  
Indiana University Center for Alzheimer's Disease and  
Related Disorders  
Indianapolis, IN

**David S. Geldmacher, MD, FANA, FACP**

Warren Family Endowed Chair in Neurology  
Director, Division of Memory Disorders and Behavioral Neurology  
Medical Director for Neurology  
University of Alabama Hospital  
University of Alabama at Birmingham  
Birmingham, AL


**Steven Jacobsen, PhD**

Chief Executive Officer/Chief Scientific Officer  
American Life Science Pharmaceuticals, Inc.  
La Jolla, CA

**Reisa A. Sperling, MD**

Professor of Neurology  
Harvard Medical School  
Director, Center for Alzheimer Research and Treatment  
Brigham and Women's Hospital  
Massachusetts General Hospital  
Boston, MA

- **Cummings:** “But a small molecule that inhibits tau formation is an exciting proposition. I do see excitement behind these preliminary observations; they provide the foundation to explore further.”
- **Geldmacher:** “It’s obviously very encouraging to see the lead compound fits well in the CNS drug space and looks more favorable than some other anti-tau compounds. It’s always good to have a compound that reduces accumulation. It’s encouraging for clinical outcomes. I see this as all very favorable for the AD space and the drug’s therapeutic potential.”
- **Boxer:** “I would agree with other panel members: the data is quite encouraging.”
- **Farlow:** “I’m also very excited, especially because this is potentially oral, as opposed to all the anti-tau antibodies that have not set the world on fire yet.”

	MILESTONES	TIME TO COMPLETION	SOURCE OF FUNDING
	Pre-IND Meeting w/FDA	July 2021	
	File IND 1Q 2022	1Q 2022	
	Phase 1a Study – SAD/MAD, <b>1<sup>st</sup> in human</b>	2Q 2023	Non-dilutive/Equity
	File IND Revision End 2022	1Q 2023	Equity funding
	Phase 1b Study - show target engagement, <b>1<sup>st</sup> in patient</b>	4Q 2023	Equity funding

## Lead Molecule: Funding Needs

- Pre-clinical pharm/tox/CMC - \$3.0MM
- Safety in healthy volunteers (Ph1a) - \$2.5MM
- Early signals of efficacy & safety in patients - \$12MM

## 2<sup>nd</sup> Generation Series:


- Early pre-clinical / toxicology studies - \$2.0MM

- **Victor P. Micati**, MBA, Chairman, former EVP Pharma. Group, former President of EU Operations Pfizer
- **James G. Moe**, Ph.D., MBA, President and CEO, Founder, Director, former bioMerieux
- **William Erhardt**, M.D., CMO, former SVP Pfizer
- **Eliot J. Davidowitz**, Ph.D., CSO, Co-Founder, Director
- **Edward Cheesman**, Ph.D., Senior Dir. Chemistry, former Bristol-Myers Squibb
- **Jack Pasini**, MBA, CCO, Director, former VP Worldwide Marketing, Pfizer
- **Robert Foerster**, MBA, CFO, former Sr. Dir. BD Pfizer
- **Paul Ginsburg**, Ph.D., J.D., In-house IP Counsel, former head Patent Dept. Pfizer, former Schering-Plough



## Completed

- Strong management team
- Highly differentiated small molecule platform
- Therapeutic and preventive in vivo efficacy
- Awarded over \$16m in NIH non-dilutive funding to date
- **Seeking funding to show clinical proof-of-concept**
  - Conduct Ph 1a to demonstrate safety in human
  - Conduct Ph 1b to demonstrate target engagement in patients (AD & PSP)



**Please direct all inquiries to:**

James Moe, Ph.D., MBA  
President and CEO  
Mobile: 646-373-6897  
Email: [jmoe@oligomerix.com](mailto:jmoe@oligomerix.com)

Jack Pasini  
Chief Commercial Officer  
Mobile: 917-912-4088  
Email: [jpasini@oligomerix.com](mailto:jpasini@oligomerix.com)